While the FDA originally approved Kalydeco to treat 10 rare gene mutations associated with the disease, the drug now can be used to treat 33 mutations.
Cystic fibrosis patients take Kalydeco — in a tablet or oral granule form — twice a day for improved lung function, among other benefits.
More articles on supply chain:
Viewpoint: Why healthcare needs more ‘me too’ drugs
FDA approves virtual reality rehab device for stroke, brain injury patients
Magellan vein-based blood tests underreported lead levels, says health officials
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
